Cargando…

Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact

Despite the significant impact of Alzheimer’s disease (AD) at individual and socioeconomic levels and the numerous research studies carried out on this topic over the last decades, the treatments available in daily clinical practice remain less than satisfactory. Among the accepted etiopathogenic hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiner, Thomas Gabriel, Popescu, Bogdan Ovidiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706225/
https://www.ncbi.nlm.nih.gov/pubmed/34945282
http://dx.doi.org/10.3390/jcm10245986
_version_ 1784622141344317440
author Schreiner, Thomas Gabriel
Popescu, Bogdan Ovidiu
author_facet Schreiner, Thomas Gabriel
Popescu, Bogdan Ovidiu
author_sort Schreiner, Thomas Gabriel
collection PubMed
description Despite the significant impact of Alzheimer’s disease (AD) at individual and socioeconomic levels and the numerous research studies carried out on this topic over the last decades, the treatments available in daily clinical practice remain less than satisfactory. Among the accepted etiopathogenic hypotheses, the amyloidogenic pathway theory, although intensively studied and even sometimes controversial, is still providing relevant theoretical elements for understanding the etiology of AD and for the further development of possible therapeutic tools. In this sense, this review aims to offer new insights related to beta amyloid (Aβ), an essential biomarker in AD. First the structure and function of Aβ in normal and pathological conditions are presented in detail, followed by a discussion on the dynamics of Aβ at the level of different biological compartments. There is focus on Aβ elimination modalities at central nervous system (CNS) level, and clearance via the blood–brain barrier seems to play a crucial/dominant role. Finally, different theoretical and already-applied therapeutic approaches for CNS Aβ elimination are presented, including the recent “peripheral sink therapeutic strategy” and “cerebrospinal fluid sinks therapeutic strategy”. These data outline the need for a multidisciplinary approach designed to deliver a solution to stimulate Aβ clearance in more direct ways, including from the cerebrospinal fluid level.
format Online
Article
Text
id pubmed-8706225
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87062252021-12-25 Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact Schreiner, Thomas Gabriel Popescu, Bogdan Ovidiu J Clin Med Review Despite the significant impact of Alzheimer’s disease (AD) at individual and socioeconomic levels and the numerous research studies carried out on this topic over the last decades, the treatments available in daily clinical practice remain less than satisfactory. Among the accepted etiopathogenic hypotheses, the amyloidogenic pathway theory, although intensively studied and even sometimes controversial, is still providing relevant theoretical elements for understanding the etiology of AD and for the further development of possible therapeutic tools. In this sense, this review aims to offer new insights related to beta amyloid (Aβ), an essential biomarker in AD. First the structure and function of Aβ in normal and pathological conditions are presented in detail, followed by a discussion on the dynamics of Aβ at the level of different biological compartments. There is focus on Aβ elimination modalities at central nervous system (CNS) level, and clearance via the blood–brain barrier seems to play a crucial/dominant role. Finally, different theoretical and already-applied therapeutic approaches for CNS Aβ elimination are presented, including the recent “peripheral sink therapeutic strategy” and “cerebrospinal fluid sinks therapeutic strategy”. These data outline the need for a multidisciplinary approach designed to deliver a solution to stimulate Aβ clearance in more direct ways, including from the cerebrospinal fluid level. MDPI 2021-12-20 /pmc/articles/PMC8706225/ /pubmed/34945282 http://dx.doi.org/10.3390/jcm10245986 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Schreiner, Thomas Gabriel
Popescu, Bogdan Ovidiu
Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title_full Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title_fullStr Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title_full_unstemmed Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title_short Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
title_sort amyloid beta dynamics in biological fluids—therapeutic impact
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706225/
https://www.ncbi.nlm.nih.gov/pubmed/34945282
http://dx.doi.org/10.3390/jcm10245986
work_keys_str_mv AT schreinerthomasgabriel amyloidbetadynamicsinbiologicalfluidstherapeuticimpact
AT popescubogdanovidiu amyloidbetadynamicsinbiologicalfluidstherapeuticimpact